vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). UNIVERSAL TECHNICAL INSTITUTE INC runs the higher net margin — 5.8% vs -14.6%, a 20.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 9.6%). Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-19.2M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 9.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
AXSM vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $220.8M |
| Net Profit | $-28.6M | $12.8M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 7.1% |
| Net Margin | -14.6% | 5.8% |
| Revenue YoY | 65.0% | 9.6% |
| Net Profit YoY | 61.9% | -42.1% |
| EPS (diluted) | $-0.55 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $220.8M | ||
| Q3 25 | $171.0M | $222.4M | ||
| Q2 25 | $150.0M | $204.3M | ||
| Q1 25 | $121.5M | $207.4M | ||
| Q4 24 | $118.8M | $201.4M | ||
| Q3 24 | $104.8M | $196.4M | ||
| Q2 24 | $87.2M | $177.5M | ||
| Q1 24 | $75.0M | $184.2M |
| Q4 25 | $-28.6M | $12.8M | ||
| Q3 25 | $-47.2M | $18.8M | ||
| Q2 25 | $-48.0M | $10.7M | ||
| Q1 25 | $-59.4M | $11.4M | ||
| Q4 24 | $-74.9M | $22.2M | ||
| Q3 24 | $-64.6M | $18.8M | ||
| Q2 24 | $-79.3M | $5.0M | ||
| Q1 24 | $-68.4M | $7.8M |
| Q4 25 | -13.8% | 7.1% | ||
| Q3 25 | -27.0% | 11.2% | ||
| Q2 25 | -24.5% | 6.9% | ||
| Q1 25 | -46.9% | 8.1% | ||
| Q4 24 | -61.1% | 13.6% | ||
| Q3 24 | -59.8% | 13.3% | ||
| Q2 24 | -89.5% | 4.2% | ||
| Q1 24 | -89.7% | 6.1% |
| Q4 25 | -14.6% | 5.8% | ||
| Q3 25 | -27.6% | 8.4% | ||
| Q2 25 | -32.0% | 5.2% | ||
| Q1 25 | -48.9% | 5.5% | ||
| Q4 24 | -63.1% | 11.0% | ||
| Q3 24 | -61.7% | 9.6% | ||
| Q2 24 | -91.0% | 2.8% | ||
| Q1 24 | -91.1% | 4.2% |
| Q4 25 | $-0.55 | $0.23 | ||
| Q3 25 | $-0.94 | $0.33 | ||
| Q2 25 | $-0.97 | $0.19 | ||
| Q1 25 | $-1.22 | $0.21 | ||
| Q4 24 | $-1.54 | $0.40 | ||
| Q3 24 | $-1.34 | $0.35 | ||
| Q2 24 | $-1.67 | $0.09 | ||
| Q1 24 | $-1.44 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $88.3M | $335.9M |
| Total Assets | $689.8M | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $162.8M | ||
| Q3 25 | $325.3M | $169.1M | ||
| Q2 25 | $303.0M | $70.7M | ||
| Q1 25 | $300.9M | $96.0M | ||
| Q4 24 | $315.4M | $172.0M | ||
| Q3 24 | $327.3M | $161.9M | ||
| Q2 24 | $315.7M | $115.5M | ||
| Q1 24 | $331.4M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $88.3M | $335.9M | ||
| Q3 25 | $73.7M | $328.1M | ||
| Q2 25 | $73.1M | $306.8M | ||
| Q1 25 | $53.2M | $293.9M | ||
| Q4 24 | $57.0M | $280.0M | ||
| Q3 24 | $92.9M | $260.2M | ||
| Q2 24 | $102.9M | $239.4M | ||
| Q1 24 | $144.0M | $232.6M |
| Q4 25 | $689.8M | $834.0M | ||
| Q3 25 | $669.3M | $826.1M | ||
| Q2 25 | $639.8M | $740.8M | ||
| Q1 25 | $596.7M | $720.4M | ||
| Q4 24 | $568.5M | $753.8M | ||
| Q3 24 | $561.5M | $744.6M | ||
| Q2 24 | $548.2M | $706.0M | ||
| Q1 24 | $545.7M | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $3.1M |
| Free Cash FlowOCF − Capex | $-18.7M | $-19.2M |
| FCF MarginFCF / Revenue | -9.6% | -8.7% |
| Capex IntensityCapex / Revenue | 0.0% | 10.1% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $3.1M | ||
| Q3 25 | $1.0M | $57.1M | ||
| Q2 25 | $-32.4M | $18.1M | ||
| Q1 25 | $-43.4M | $-789.0K | ||
| Q4 24 | $-26.2M | $23.0M | ||
| Q3 24 | $-18.6M | $67.5M | ||
| Q2 24 | $-30.1M | $10.0M | ||
| Q1 24 | $-53.5M | $-2.5M |
| Q4 25 | $-18.7M | $-19.2M | ||
| Q3 25 | $988.0K | $40.6M | ||
| Q2 25 | $-32.4M | $6.8M | ||
| Q1 25 | $-43.7M | $-11.7M | ||
| Q4 24 | $-26.2M | $19.6M | ||
| Q3 24 | $-18.7M | $60.0M | ||
| Q2 24 | $-30.2M | $3.0M | ||
| Q1 24 | $-53.6M | $-8.4M |
| Q4 25 | -9.6% | -8.7% | ||
| Q3 25 | 0.6% | 18.3% | ||
| Q2 25 | -21.6% | 3.4% | ||
| Q1 25 | -36.0% | -5.7% | ||
| Q4 24 | -22.1% | 9.7% | ||
| Q3 24 | -17.9% | 30.6% | ||
| Q2 24 | -34.6% | 1.7% | ||
| Q1 24 | -71.4% | -4.6% |
| Q4 25 | 0.0% | 10.1% | ||
| Q3 25 | 0.0% | 7.4% | ||
| Q2 25 | 0.0% | 5.5% | ||
| Q1 25 | 0.3% | 5.3% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.1% | 3.8% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | — | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
